(Q59217938)

English

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study

article

In more languages

Statements

scholarly article

0 references

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study (English)

0 references

United States of America

0 references

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

plaque psoriasis

1 reference

based on heuristic

inferred from title

Steven R. Feldman

object named as

Steven Feldman

3

0 references

author name string

Dennis A Revicki

1

0 references

Alan Menter

2

0 references

Miriam Kimel

4

0 references

Neesha Harnam

5

0 references

Mary K Willian

6

0 references

language of work or name

0 references

publication date

2 October 2008

0 references

Health and Quality of Life Outcomes

0 references

6

0 references

1

0 references

75

0 references

https://scigraph.springernature.com/pub.10.1186/1477-7525-6-75

0 references

The impact of psoriasis on psychosocial life domains. A review

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The burden of psoriasis is not determined by disease severity only.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life assessments in dermatology

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psoriasis causes as much disability as other major medical diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating clinically significant differences in quality of life outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An Italian study on psoriasis and depression

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of psoriasis on quality of life

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Social coping strategies associated with quality of life decrements among psoriasis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do SF-36 summary component scores accurately summarize subscale scores?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantifying the harmful effect of psoriasis on health-related quality of life

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alefacept therapy produces remission for patients with chronic plaque psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept as monotherapy in patients with psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of etanercept as monotherapy for psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SF-36 summary scores: are physical and mental health truly distinct?

1 reference

https://pubmed.ncbi.nlm.nih.gov/18831744

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1477-7525-6-75

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59217938&oldid=1779912924"